Abstract:The aim of the study was to evaluate the presence of aromatase cytochrome P450 enzyme (P450AROM) expression in normal pituitary tissues and tumor tissues of patients with prolactinoma and to examine the impact of the P450AROM expression on clinical outcome. Twenty-six consecutive human pituitary tissue samples were obtained from autopsies performed at the Institute of Forensic Medicine. Sixty-four patients who had an adenomectomy between 2000 and 2009 after prolactinoma diagnosis with histologically confirmed … Show more
“…Similarly, in the study of Akıncı et al, ER-beta expression was seen higher in controls and invasive adenomas than noninvasive adenomas, although the difference was not statistically significant [4]. In addition, the relationship between aromatase and ER-beta expression was negatively directed but not statistically significant [4]. We observed a significant negative correlation between aromatase and ERalpha expression.…”
Section: Discussionsupporting
confidence: 80%
“…In contrast to aromatase expression, ERalpha expression was lower in the acromegaly group than in normal pituitary tissue. The role of local aromatization in prolactinoma has recently been shown by Akıncı et al In his study, aromatase expression was found to be higher in prolactinomas than in normal pituitary tissue, particularly in males with invasive adenoma, but no significant relationships were detected among p53, Ki-67, remission status, and aromatase expression [4]. Moreover, aromatase expression has also been observed in females with prolactinomas [26].…”
Section: Discussionmentioning
confidence: 70%
“…Many different cell types have been shown to express aromatase, including neurons, preadipocytes, fibroblasts, and gonadal cells, suggesting local estrogen synthesis by these cells [1][2][3]. The local conversion of testosterone to estrogen is important in normal physiology as well as in estrogen-induced tumor formation [4]. After discovery of the aromatase expression in the brain, the significance of local estrogen production in the regulation of reproductive process, sexual behavior, cognition, and recovery from neuronal injury have been shown in several studies [5][6][7].…”
Section: Introductionmentioning
confidence: 99%
“…Testosterone replacement has been also shown to elevate prolactin levels and to cause tumor growth in patients with prolactinoma [12]. After this growing evidence, aromatase expression has been observed in human prolactinoma tissues and suggested to affect tumor behavior [4]. In a recent study, treatment of male rat pituitary prolactin-producing cells in vivo with aromatase inhibitor and testosterone has shown the regulatory effect of aromatase on pituitary functions [13].…”
The purpose of this study was to evaluate aromatase enzyme expression in growth hormone (GH) secreting adenomas and comparison with prolactinomas, nonfunctional adenomas, and normal pituitary tissues. Also the impact of its expression on clinical and prognostic features was evaluated. 38 acromegaly, 26 prolactinoma, and 31 nonfunctional pituitary adenoma and 11 normal pituitary gland samples from autopsies were included. Aromatase and estrogen receptor-alpha (ERα) were evaluated by Immunohistochemical method; demographic, pre- and postoperative features of the patients were noted. Aromatase was expressed in varying degrees in all cases in study including controls. Aromatase expression in patients with acromegaly was significantly higher than patients with prolactinoma, nonfunctional adenoma, and controls (p = 0.04, p = 0.01 and p < 0.001, respectively). Taken together two functional adenoma groups, prolactinoma and acromegaly, aromatase expression was negatively correlated with ER-alpha (p = 0.02, r = -0.34). Also, Ki-67 immunohistochemical results were negatively correlated with aromatase expression (p = 0.03, r = -0.27) while positively correlated with ER expression (p < 0.01). Consistent with the growing evidence about testosterone effect on pituitary functions, aromatase expression was found to be higher in GH-secreting pituitary adenoma. Aromatase was expressed in all pituitary tissues including autopsy samples; however, it was highest in patients with acromegaly. In patients with acromegaly and prolactinoma, aromatase expression was negatively correlated with Ki-67 score, and also it was higher in patients with complete postoperative remission than without remission. Therefore, aromatase expression may be a good prognostic marker predominantly in acromegaly.
“…Similarly, in the study of Akıncı et al, ER-beta expression was seen higher in controls and invasive adenomas than noninvasive adenomas, although the difference was not statistically significant [4]. In addition, the relationship between aromatase and ER-beta expression was negatively directed but not statistically significant [4]. We observed a significant negative correlation between aromatase and ERalpha expression.…”
Section: Discussionsupporting
confidence: 80%
“…In contrast to aromatase expression, ERalpha expression was lower in the acromegaly group than in normal pituitary tissue. The role of local aromatization in prolactinoma has recently been shown by Akıncı et al In his study, aromatase expression was found to be higher in prolactinomas than in normal pituitary tissue, particularly in males with invasive adenoma, but no significant relationships were detected among p53, Ki-67, remission status, and aromatase expression [4]. Moreover, aromatase expression has also been observed in females with prolactinomas [26].…”
Section: Discussionmentioning
confidence: 70%
“…Many different cell types have been shown to express aromatase, including neurons, preadipocytes, fibroblasts, and gonadal cells, suggesting local estrogen synthesis by these cells [1][2][3]. The local conversion of testosterone to estrogen is important in normal physiology as well as in estrogen-induced tumor formation [4]. After discovery of the aromatase expression in the brain, the significance of local estrogen production in the regulation of reproductive process, sexual behavior, cognition, and recovery from neuronal injury have been shown in several studies [5][6][7].…”
Section: Introductionmentioning
confidence: 99%
“…Testosterone replacement has been also shown to elevate prolactin levels and to cause tumor growth in patients with prolactinoma [12]. After this growing evidence, aromatase expression has been observed in human prolactinoma tissues and suggested to affect tumor behavior [4]. In a recent study, treatment of male rat pituitary prolactin-producing cells in vivo with aromatase inhibitor and testosterone has shown the regulatory effect of aromatase on pituitary functions [13].…”
The purpose of this study was to evaluate aromatase enzyme expression in growth hormone (GH) secreting adenomas and comparison with prolactinomas, nonfunctional adenomas, and normal pituitary tissues. Also the impact of its expression on clinical and prognostic features was evaluated. 38 acromegaly, 26 prolactinoma, and 31 nonfunctional pituitary adenoma and 11 normal pituitary gland samples from autopsies were included. Aromatase and estrogen receptor-alpha (ERα) were evaluated by Immunohistochemical method; demographic, pre- and postoperative features of the patients were noted. Aromatase was expressed in varying degrees in all cases in study including controls. Aromatase expression in patients with acromegaly was significantly higher than patients with prolactinoma, nonfunctional adenoma, and controls (p = 0.04, p = 0.01 and p < 0.001, respectively). Taken together two functional adenoma groups, prolactinoma and acromegaly, aromatase expression was negatively correlated with ER-alpha (p = 0.02, r = -0.34). Also, Ki-67 immunohistochemical results were negatively correlated with aromatase expression (p = 0.03, r = -0.27) while positively correlated with ER expression (p < 0.01). Consistent with the growing evidence about testosterone effect on pituitary functions, aromatase expression was found to be higher in GH-secreting pituitary adenoma. Aromatase was expressed in all pituitary tissues including autopsy samples; however, it was highest in patients with acromegaly. In patients with acromegaly and prolactinoma, aromatase expression was negatively correlated with Ki-67 score, and also it was higher in patients with complete postoperative remission than without remission. Therefore, aromatase expression may be a good prognostic marker predominantly in acromegaly.
“…Moreover, we reported a very strong correlation between the pituitary expression of aromatase and the incidence of spontaneous prolactinomas in old rats [3] and humans [4]. Similar results were later reported by different authors in non-tumoral pituitaries of humans and different animal species [5]–[11] and in human prolactinomas [12]. However, the physiological relevance of aromatase and the possible aromatization of testosterone to estradiol in the regulation of pituitary hormones are not well known.…”
In previous studies we demonstrated the immunohistochemical expression of aromatase in pituitary cells. In order to determine whether pituitary aromatase is involved in the paracrine regulation of prolactin-producing pituitary cells and the physiological relevance of pituitary aromatase in the control of these cells, an in vivo and in vitro immunocytochemical and morphometric study of prolactin-positive pituitary cells was carried out on the pituitary glands of adult male rats treated with the aromatase antagonist fadrozole. Moreover, we analyzed the expression of mRNA for the enzyme in pituitary cells of male adult rats by in situ hybridization. The aromatase-mRNA was seen to be located in the cytoplasm of 41% of pituitary cells and was well correlated with the immunocytochemical staining. After in vivo treatment with fadrozole, the size (cellular and nuclear areas) of prolactin cells, as well as the percentage of prolactin-positive cells and the percentage of proliferating-prolactin cells, was significantly decreased. Moreover, fadrozole decreased serum prolactin levels. In vitro, treatment with fadrozole plus testosterone induced similar effects on prolactin-positive cells, inhibiting their cellular proliferation. Our results suggest that under physiological conditions aromatase P450 exerts a relevant control over male pituitary prolactin-cells, probably transforming testosterone to estradiol in the pituitary gland.
Many significant genes have been identified and validated in prolactinomas and most have not been fully analyzed for therapeutic and diagnostic potential. These genes could become candidate molecular targets for biomarker development and precision drug targeting as well as catalyze deeper research efforts utilizing next generation profiling/sequencing techniques, particularly genome scale expression and epigenomic analyses.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.